Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcumin-preconditioned autologous adipose-derived stem cells (ASCs) are an experimental cellular therapy developed by the University of the Punjab for facial reconstructive surgery. This approach involves isolating ASCs from a patient's own adipose tissue, culturing them, and preconditioning them with curcumin—a bioactive polyphenol—prior to fat grafting. Curcumin preconditioning is intended to enhance the survival, proliferation, and pro-angiogenic potential of the stem cells by modulating oxidative stress and inflammatory pathways. When these enriched cells are co-administered with autologous fat grafts, they aim to improve graft volume retention and reduce resorption rates in patients with facial contour deformities such as Romberg disease, craniofacial microsomia, and various types of scarring.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin-preconditioned autologous adipose-derived stem cells.